4.6 Review

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma

Journal

CANCERS
Volume 13, Issue 9, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13092043

Keywords

uveal; immunotherapy; BAP1; tumor microenvironment; anti-PD-1; anti-CTLA-4; TIL

Categories

Funding

  1. Italian Ministry of Health 5x1000 Funds 2013
  2. Fondazione San Paolo [20067]
  3. Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 17103]

Ask authors/readers for more resources

Despite improvements in early identification and control of primary uveal melanoma, 50% of patients develop metastatic disease with little efficacy from targeted therapies. Immunotherapy, although effective in cutaneous melanoma, shows limited results in treating uveal melanoma due to its unique tumor microenvironment and immune responses.
Simple Summary Despite improvements in the early identification and successful control of primary uveal melanoma, 50% of patients will develop metastatic disease with only marginal improvements in survival. This review focuses on the tumor microenvironment and the cross-talk between tumor and immune cells in a tumor characterized by low mutational load, the induction of immune-suppressive cells, and the expression of alternative immune checkpoint molecules. The choice of combining different strategies of immunotherapy remains a feasible and promising option on selected patients. Uveal melanoma (UM), though a rare form of melanoma, is the most common intraocular tumor in adults. Conventional therapies of primary tumors lead to an excellent local control, but 50% of patients develop metastases, in most cases with lethal outcome. Somatic driver mutations that act on the MAP-kinase pathway have been identified, yet targeted therapies show little efficacy in the clinics. No drugs are currently available for the G protein alpha subunits GNAQ and GNA11, which are the most frequent driver mutations in UM. Drugs targeting the YAP-TAZ pathway that is also activated in UM, the tumor-suppressor gene BRCA1 Associated Protein 1 (BAP1) and the Splicing Factor 3b Subunit 1 gene (SF3B1) whose mutations are associated with metastatic risk, have not been developed yet. Immunotherapy is highly effective in cutaneous melanoma but yields only poor results in the treatment of UM: anti-PD-1 and anti-CTLA-4 blocking antibodies did not meet the expectations except for isolated cases. Here, we discuss how the improved knowledge of the tumor microenvironment and of the cross-talk between tumor and immune cells could help to reshape anti-tumor immune responses to overcome the intrinsic resistance to immune checkpoint blockers of UM. We critically review the dogma of low mutational load, the induction of immune-suppressive cells, and the expression of alternative immune checkpoint molecules. We argue that immunotherapy might still be an option for the treatment of UM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available